Medicure (OTCMKTS:MCUJF – Get Free Report) and Xeris Biopharma (NASDAQ:XERS – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk.
Profitability
This table compares Medicure and Xeris Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Medicure | -13.10% | -17.91% | -11.95% |
| Xeris Biopharma | -5.88% | N/A | -4.66% |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Medicure and Xeris Biopharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Medicure | 0 | 0 | 0 | 0 | 0.00 |
| Xeris Biopharma | 1 | 2 | 5 | 0 | 2.50 |
Valuation & Earnings
This table compares Medicure and Xeris Biopharma”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Medicure | $15.99 million | 0.52 | -$760,000.00 | ($0.24) | -3.30 |
| Xeris Biopharma | $203.07 million | 5.65 | -$54.84 million | ($0.10) | -69.10 |
Medicure has higher earnings, but lower revenue than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Medicure, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
42.8% of Xeris Biopharma shares are owned by institutional investors. 12.9% of Medicure shares are owned by insiders. Comparatively, 6.5% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Volatility and Risk
Medicure has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.
Summary
Xeris Biopharma beats Medicure on 10 of the 14 factors compared between the two stocks.
About Medicure
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
About Xeris Biopharma
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
